Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

SYK US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

SYK US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Stryker Corp(SYK US)

$312.39-6.402.01%Ext:$321.32+8.932.86%(Pre-Market · 10:48:58 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Stryker Corp(SYK US)

$312.39-6.402.01%Ext:$321.32+8.932.86%(Pre-Market · 10:48:58 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Stryker Corp — Company Profile

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Kevin A. Lobo
Headquarters
Portage, MI, US
IPO Date
Mar 17, 1980
Employees
56,000
Website
www.stryker.com

Key Metrics

Price
$275.43
Market Cap
$105.59B
Revenue (TTM)
$6.02B
Net Income (TTM)
$745.00M
EPS (TTM)
1.95
P/E (TTM)
31.64
P/B (TTM)
4.60
Dividend Yield
114.06%
ROE (TTM)

Stryker Corp — Company Profile

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Kevin A. Lobo
Headquarters
Portage, MI, US
IPO Date
Mar 17, 1980
Employees
56,000
Website
www.stryker.com

Key Metrics

Price
$275.43
Market Cap
$105.59B
Revenue (TTM)
$6.02B
Net Income (TTM)
$745.00M
EPS (TTM)
1.95
P/E (TTM)
31.64
P/B (TTM)
4.60
Dividend Yield
114.06%
ROE (TTM)
3.24%
ROA (TTM)
1.61%
Operating Margin
15.55%
Beta
0.17

Dividends

Last Dividend
$0.88
Last Yield
1.14%

Summary

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Website
www.stryker.com
Location
Portage, MI, US
Phone269 385 2600
Employees56,000
CEOKevin A. Lobo
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.8K)

Expand
  • Form 4STRYKER RONDA E9 Nov
  • 8-Kwww.stryker.comNovember 9, 20269 Nov
  • Form 144STRYKER RONDA E5 Nov
  • S-3ASRAutomatic shelf registration statement (S-3)4 Nov
  • IRANNOTICEIRANNOTICE30 Oct
  • 10-QQ3ended 30 Sept 202630 Oct
  • 8-KResults of Operations and Financial Condition29 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers6 Oct
  • Form 4Wells Preston Wendell28 Sep
  • Form 4Wells Preston Wendell24 Sep
  • Form 3Baculik Emily Kay8 Sep
  • Form 4BRAINERD MARY K2 Sep
  • Form 4Crotty Dylan Bram26 Aug
  • Form 4STRYKER RONDA E20 Aug
  • Form 4King Debra18 Aug
  • Form 144King Debra18 Aug
  • Form 144STRYKER RONDA E17 Aug
  • Form 4Montagnino Kimberly Ann4 Aug
  • Form 4King Debra4 Aug
  • Form 4Fletcher Robert S4 Aug

News

  • Stryker announces intention to nominate Jim Davis to board of directors9 Nov
  • Stryker Corporation $SYK Stock: Commonwealth Equity Services LLC Trims Position9 Nov
  • Stryker Corporation $SYK Shares Sold by Chicago Partners Investment Group LLC9 Nov
  • Stryker Corporation $SYK Shares Sold by Candriam S.C.A.9 Nov
  • 3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years7 Nov
  • Diamond Hill Large Cap Fund Q3 2026 Portfolio Update6 Nov
  • 3,649 Stryker Corporation $SYK Shares Sold by Boston Trust Walden Corp5 Nov
  • Stryker Corporation $SYK Stock Bought by International Assets Investment Management LLC2 Nov
  • SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut30 Oct
  • Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS30 Oct
  • SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook30 Oct
  • What Stryker (SYK) Said on Its Q3 Earnings Call30 Oct
  • Stryker Analysts Cut Their Forecasts Following Downbeat Q3 Earnings30 Oct
  • Stryker's Guidance Cut Rattles Investors: What It Really Says About 202730 Oct
  • Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript29 Oct
  • Stryker (SYK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates29 Oct
  • Stryker (SYK) Q3 Earnings and Revenues Lag Estimates29 Oct
  • Stryker Q3 2026 Earnings Call Transcript29 Oct
  • Stryker reports third quarter 2026 operating results29 Oct
  • SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?28 Oct

Mentions in Filings

  • … member of the board of directors of Harley-Davidson and serves as a member of the audit and finance committee and as chair of the nominating and corporate governance committee. He also served on the board of directors of <strong>Stryker</strong> Corporation from January 2011 to May 2025. Mr. Golston brings to the T. Rowe Price Group Board significant governance experience from serving on boards of global companies, accounting and financial reporting experience, a …
    T. Rowe Price Exchange-Traded Funds, Inc.Stryker Corp·485APOS - Post-effective amendment (open-end investment companies)·Q4 26·10 Nov
  • … tial revenue contributions beginning in 2027. Founded in 1986, AMI is an established Israeli distributor of advanced medical technologies, representing some of the world’s leading medical device manufacturers, including <strong>Stryker</strong>. Its orthopedic portfolio encompasses sports medicine, knee and joint replacement, surgical robotics and other advanced surgical technologies. AMI also provides clinical training, technical support and implementation serv …
    REGENTIS BIOMATERIALS LTD.Stryker Corp·EX-99.1 - 6-K - Current report (foreign private issuer)·Q4 26·9 Nov
  • Capability Orthofix ~$834M TTM Medtronic ~$5.3B Cranial & Spine Globus / NuVasive ~$2.5B Spine Alphatec ~$764M FY2025 <strong>Stryker</strong> ~$10.9B Ortho Enovis ~$2.2B FY2025 Spinal Implants ~$10.1B TAM Growing Share Deformity/cervical focus; Top 30 U.S. distributors ~80% of spine implant sales #1 Global ~$3.2B spine rev; AiBLE ecosystem; Mazor X robotics #2 Global ~$2.5B combined; ExcelsiusGPS robotics; MIS leader Fastest Growing $764M FY25 +25%; lateral/defo …
    Orthofix Medical Inc.Stryker Corp·EX-99.2 - 8-K - Results of Operations and Financial Condition·Q4 26·9 Nov
  • … anuary 1, 2032 were exempt from the rule. Given our previously announced coal unit retirement commitments, our Martin Lake and Oak Grove plants were the only coal units subject to the 2024 Rule. Our Graham, Lake Hubbard, <strong>Stryker</strong> Creek and Trinidad oil/natural gas facilities were also regulated under the 2024 Rule. None of our existing large or small combustion turbines were subject to the 2024 Rule, and if the proposal to fully repeal the 2024 Ru …
    Vistra Corp.Stryker Corp·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • On March 25, 2025, the Company entered into an agreement with its primary legal counsel related to the pending patent and unfair competition dispute with <strong>Stryker Corporation</strong> and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") to defer payment of certain legal costs incurred in 2025 and 2026 related to the dispute. The agreement anticipates that the amount financed by the Company would not exceed $5.0 million over this two …
    TREACE MEDICAL CONCEPTS, INC.Stryker Corp·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • … und,” said Dr. Menawat. “Jason brings a valuable combination of operating strategy, sector knowledge and capital markets experience. Having known him since his coverage of Novadaq Technologies up until its acquisition by <strong>Stryker</strong> for approximately $701 million, I look forward to his perspective on growth opportunities and capital allocation.” **Conference Call Details** Profound is pleased to invite all interested parties to participate in a con …
    Profound Medical Corp.Stryker Corp·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·5 Nov

Key Stats

Trading

Px/Chg 1D$275.43 / +0.90%
Avg Volume2.41M
Beta0.17
Mkt Cap105.59B
FD Mkt Cap124.98B

Float

Shrs Out/Float383.36M / 347.76M
Short Float0.02%
Days to Cover2.36
Stock Repurchased$0.00

Current Valuation

EV117.95B
EV/EBITDA19.14
EV/Sales4.67
P/B4.60
P/S4.18
FCF Yield0.39%
ROE3.24%
ROA1.61%
Current Ratio2.11

Dividend

Cash$0.88
Yield114.06%
Yield (TTM)114.06%

Estimates

P/E31.64
Est P/E0.00
Est EPS2.98
Est PEG0.00

Valuation

Metric5Yr AvgMay '23Apr '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings81.2848.1040.3647.61128.61141.73
Price / Sales10.296.156.236.3115.2317.54
Price / Book Value6.016.836.876.914.874.60
Price / Free Cash Flow89.9955.7140.7340.8658.24254.43
ENTERPRISE VALUE METRICS
Enterprise Value131,160.7125,100.4138,258.4152,958.2121,541.3117,945.1
Enterprise Value / Sales11.376.786.746.7716.9519.59
Enterprise Value / EBITDA48.0431.1327.3430.9859.8790.87
Enterprise Value / EBIT60.8341.4234.3239.3470.91118.18

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue10.1%17,108.018,449.020,498.022,595.025,116.0
Gross Income10.7%10,709.011,040.012,494.013,980.016,065.0
EBITDA15%3,608.04,018.05,057.04,938.06,314.0
EBIT18.3%2,618.03,020.04,029.03,888.05,121.0
Net Income13%1,994.02,358.03,165.02,993.03,246.0
EPS (Diluted)12.6%5.226.178.257.768.40
BALANCE SHEET
Cash & ST Inv8%3,019.01,928.03,053.04,493.04,100.0
Total Assets8.4%34,631.036,884.039,912.042,971.047,844.0
Total Liabilities6.5%19,754.020,268.021,319.022,337.025,424.0
Total Shareholder Equity10.8%14,877.016,616.018,593.020,634.022,420.0
CASH FLOW
Net Operating Cash Flow11.5%3,263.02,624.03,711.04,242.05,044.0
Cap Ex9.7%-525.0-588.0-575.0-755.0-761.0
Free Cash Flow11.8%2,738.02,036.03,136.03,487.04,283.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)309.64
Basic Shares383.36
Market Cap118,703.8
Diluted Shares384.70
Fully Diluted Shares Outstanding384.70
Fully Diluted Market Cap119,118.5
+Consolidated Debt15,433.0
−In-the-Money Convertible Debt—
+Capital Leases343.0
+Operating Leases—
−Cash & Equivalents-3,271.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value130,865.8

Segment data

Revenue

by Products and services

  • Medsurg62%
  • Orthopaedics38%

Revenue

by Geography

  • Emea52%
  • Asia Pacific35%
  • Other Foreign Countries13%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US

3.24%
ROA (TTM)
1.61%
Operating Margin
15.55%
Beta
0.17

Dividends

Last Dividend
$0.88
Last Yield
1.14%

Summary

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Website
www.stryker.com
Location
Portage, MI, US
Phone269 385 2600
Employees56,000
CEOKevin A. Lobo
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.8K)

Expand
  • Form 4STRYKER RONDA E9 Nov
  • 8-Kwww.stryker.comNovember 9, 20269 Nov
  • Form 144STRYKER RONDA E5 Nov
  • S-3ASRAutomatic shelf registration statement (S-3)4 Nov
  • IRANNOTICEIRANNOTICE30 Oct
  • 10-QQ3ended 30 Sept 202630 Oct
  • 8-KResults of Operations and Financial Condition29 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers6 Oct
  • Form 4Wells Preston Wendell28 Sep
  • Form 4Wells Preston Wendell24 Sep
  • Form 3Baculik Emily Kay8 Sep
  • Form 4BRAINERD MARY K2 Sep
  • Form 4Crotty Dylan Bram26 Aug
  • Form 4STRYKER RONDA E20 Aug
  • Form 4King Debra18 Aug
  • Form 144King Debra18 Aug
  • Form 144STRYKER RONDA E17 Aug
  • Form 4Montagnino Kimberly Ann4 Aug
  • Form 4King Debra4 Aug
  • Form 4Fletcher Robert S4 Aug

News

  • Stryker announces intention to nominate Jim Davis to board of directors9 Nov
  • Stryker Corporation $SYK Stock: Commonwealth Equity Services LLC Trims Position9 Nov
  • Stryker Corporation $SYK Shares Sold by Chicago Partners Investment Group LLC9 Nov
  • Stryker Corporation $SYK Shares Sold by Candriam S.C.A.9 Nov
  • 3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years7 Nov
  • Diamond Hill Large Cap Fund Q3 2026 Portfolio Update6 Nov
  • 3,649 Stryker Corporation $SYK Shares Sold by Boston Trust Walden Corp5 Nov
  • Stryker Corporation $SYK Stock Bought by International Assets Investment Management LLC2 Nov
  • SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut30 Oct
  • Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS30 Oct
  • SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook30 Oct
  • What Stryker (SYK) Said on Its Q3 Earnings Call30 Oct
  • Stryker Analysts Cut Their Forecasts Following Downbeat Q3 Earnings30 Oct
  • Stryker's Guidance Cut Rattles Investors: What It Really Says About 202730 Oct
  • Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript29 Oct
  • Stryker (SYK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates29 Oct
  • Stryker (SYK) Q3 Earnings and Revenues Lag Estimates29 Oct
  • Stryker Q3 2026 Earnings Call Transcript29 Oct
  • Stryker reports third quarter 2026 operating results29 Oct
  • SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?28 Oct

Mentions in Filings

  • … member of the board of directors of Harley-Davidson and serves as a member of the audit and finance committee and as chair of the nominating and corporate governance committee. He also served on the board of directors of <strong>Stryker</strong> Corporation from January 2011 to May 2025. Mr. Golston brings to the T. Rowe Price Group Board significant governance experience from serving on boards of global companies, accounting and financial reporting experience, a …
    T. Rowe Price Exchange-Traded Funds, Inc.Stryker Corp·485APOS - Post-effective amendment (open-end investment companies)·Q4 26·10 Nov
  • … tial revenue contributions beginning in 2027. Founded in 1986, AMI is an established Israeli distributor of advanced medical technologies, representing some of the world’s leading medical device manufacturers, including <strong>Stryker</strong>. Its orthopedic portfolio encompasses sports medicine, knee and joint replacement, surgical robotics and other advanced surgical technologies. AMI also provides clinical training, technical support and implementation serv …
    REGENTIS BIOMATERIALS LTD.Stryker Corp·EX-99.1 - 6-K - Current report (foreign private issuer)·Q4 26·9 Nov
  • Capability Orthofix ~$834M TTM Medtronic ~$5.3B Cranial & Spine Globus / NuVasive ~$2.5B Spine Alphatec ~$764M FY2025 <strong>Stryker</strong> ~$10.9B Ortho Enovis ~$2.2B FY2025 Spinal Implants ~$10.1B TAM Growing Share Deformity/cervical focus; Top 30 U.S. distributors ~80% of spine implant sales #1 Global ~$3.2B spine rev; AiBLE ecosystem; Mazor X robotics #2 Global ~$2.5B combined; ExcelsiusGPS robotics; MIS leader Fastest Growing $764M FY25 +25%; lateral/defo …
    Orthofix Medical Inc.Stryker Corp·EX-99.2 - 8-K - Results of Operations and Financial Condition·Q4 26·9 Nov
  • … anuary 1, 2032 were exempt from the rule. Given our previously announced coal unit retirement commitments, our Martin Lake and Oak Grove plants were the only coal units subject to the 2024 Rule. Our Graham, Lake Hubbard, <strong>Stryker</strong> Creek and Trinidad oil/natural gas facilities were also regulated under the 2024 Rule. None of our existing large or small combustion turbines were subject to the 2024 Rule, and if the proposal to fully repeal the 2024 Ru …
    Vistra Corp.Stryker Corp·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • On March 25, 2025, the Company entered into an agreement with its primary legal counsel related to the pending patent and unfair competition dispute with <strong>Stryker Corporation</strong> and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") to defer payment of certain legal costs incurred in 2025 and 2026 related to the dispute. The agreement anticipates that the amount financed by the Company would not exceed $5.0 million over this two …
    TREACE MEDICAL CONCEPTS, INC.Stryker Corp·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • … und,” said Dr. Menawat. “Jason brings a valuable combination of operating strategy, sector knowledge and capital markets experience. Having known him since his coverage of Novadaq Technologies up until its acquisition by <strong>Stryker</strong> for approximately $701 million, I look forward to his perspective on growth opportunities and capital allocation.” **Conference Call Details** Profound is pleased to invite all interested parties to participate in a con …
    Profound Medical Corp.Stryker Corp·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·5 Nov

Key Stats

Trading

Px/Chg 1D$275.43 / +0.90%
Avg Volume2.41M
Beta0.17
Mkt Cap105.59B
FD Mkt Cap124.98B

Float

Shrs Out/Float383.36M / 347.76M
Short Float0.02%
Days to Cover2.36
Stock Repurchased$0.00

Current Valuation

EV117.95B
EV/EBITDA19.14
EV/Sales4.67
P/B4.60
P/S4.18
FCF Yield0.39%
ROE3.24%
ROA1.61%
Current Ratio2.11

Dividend

Cash$0.88
Yield114.06%
Yield (TTM)114.06%

Estimates

P/E31.64
Est P/E0.00
Est EPS2.98
Est PEG0.00

Valuation

Metric5Yr AvgMay '23Apr '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings81.2848.1040.3647.61128.61141.73
Price / Sales10.296.156.236.3115.2317.54
Price / Book Value6.016.836.876.914.874.60
Price / Free Cash Flow89.9955.7140.7340.8658.24254.43
ENTERPRISE VALUE METRICS
Enterprise Value131,160.7125,100.4138,258.4152,958.2121,541.3117,945.1
Enterprise Value / Sales11.376.786.746.7716.9519.59
Enterprise Value / EBITDA48.0431.1327.3430.9859.8790.87
Enterprise Value / EBIT60.8341.4234.3239.3470.91118.18

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue10.1%17,108.018,449.020,498.022,595.025,116.0
Gross Income10.7%10,709.011,040.012,494.013,980.016,065.0
EBITDA15%3,608.04,018.05,057.04,938.06,314.0
EBIT18.3%2,618.03,020.04,029.03,888.05,121.0
Net Income13%1,994.02,358.03,165.02,993.03,246.0
EPS (Diluted)12.6%5.226.178.257.768.40
BALANCE SHEET
Cash & ST Inv8%3,019.01,928.03,053.04,493.04,100.0
Total Assets8.4%34,631.036,884.039,912.042,971.047,844.0
Total Liabilities6.5%19,754.020,268.021,319.022,337.025,424.0
Total Shareholder Equity10.8%14,877.016,616.018,593.020,634.022,420.0
CASH FLOW
Net Operating Cash Flow11.5%3,263.02,624.03,711.04,242.05,044.0
Cap Ex9.7%-525.0-588.0-575.0-755.0-761.0
Free Cash Flow11.8%2,738.02,036.03,136.03,487.04,283.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)309.64
Basic Shares383.36
Market Cap118,703.8
Diluted Shares384.70
Fully Diluted Shares Outstanding384.70
Fully Diluted Market Cap119,118.5
+Consolidated Debt15,433.0
−In-the-Money Convertible Debt—
+Capital Leases343.0
+Operating Leases—
−Cash & Equivalents-3,271.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value130,865.8

Segment data

Revenue

by Products and services

  • Medsurg62%
  • Orthopaedics38%

Revenue

by Geography

  • Emea52%
  • Asia Pacific35%
  • Other Foreign Countries13%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US